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1. Introduction
Infectious diseases are responsible for a considerable number of deaths in infectious in entire
world. Infectious diseases are human diseases caused by viruses, bacteria, parasites, fungi and
other microorganisms. Most of them have been controlled by vaccines or antimicrobials.
However, some of them still represent global public health problems and are being monitored
by the WHO and Center for Disease Control and Prevention. This chapter provides an
overview of the applications of molecular methods for infectious diseases caused by viruses
(intracellular obligate parasites) of global impact such as Dengue virus, Hepatitis B virus or
influenza A virus. The infectious diseases not only represent a potential danger to the life of
all human beings but also a significant investment in its detection, treatment and control of
their spread. The increase in opportunities of infection by globalization, high rates of mobility
among most countries around the world, the patient susceptibility to diseases due to genetic
variation in populations [1], the ability of the microorganisms to evade the host immune
response has forced the World Health Organization (WHO) to establish better methods of
detection, prevention and control of infectious diseases caused by viruses as influenza A virus,
coronaviruses, dengue virus, among others [2]. On the other hand, some types of cancer are
the result of chronic viral infections caused by human papillomavirus, hepatitis B and C virus.
Other infectious diseases are related to the development of neurological disorders caused by
the measles virus, or human immunodeficiency virus [3]. In the determination of the etiology
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of such diseases has made extensive use of clinical procedures internationally validated as
methods based on viral cultures and serological assays. However, it is increasing the use of
nucleic acid tests in the diagnosis of infectious disease of viral etiology, considering that a
critical step to proper treatment and control of any virus infection is a correct diagnosis.
Diagnostic tests based on nucleic acid (NAT, nucleic acid tests) more used are the nucleic acid
sequence-based amplification (NASBA), polymerase chain reaction (PCR) or real-time PCR for
virus detection, genotyping and quantification. In addition, the automation of these techniques
decrease in test time, low contamination risk, ease of performance, speed and have lower
detection limits [4] show the relevance of their use. The detection of the infectious agent can
be done by detection of the genomic DNA, genomic ARN and the viral messenger RNA
(mRNA) using the follow techniques: Nucleic acids hybridization (Solid-phase, Liquid-phase
or in situ hybridization), amplification of the signal of nucleic acids (branched-DNA assays
and Hybrid capture assays), nucleic acid amplification (PCR, Real-Time PCR, Nested PCR,
Multiplex PCR, Transcriptional-based amplification methods coupled to qPCR or NASBA,
Strand displacement amplification), Microarrays (DNA microarrays and Multiplexed micro‐
sphere-base array) [5]. Currently there are some variants of the above techniques aimed to
screening for detection or simultaneous discrimination of various etiological agents using
multiplex PCR techniques [6], MassTag PCR, a PCR platform coupled to a mass spectrometer
which allows simultaneous detection of >20 different pathogens [7] or microarrays pathogen
detection (Virochip) [8]. The routine use of molecular techniques for the fast differential
diagnosis of viral infections is vital for a high quality care of the patient with an infectious
disease, directs the best therapeutic scheme, thus reducing the likelihood of complications, the
proper choice of antiviral drug or the best strategy for control of viral replication, reduces
resistance to antivirals and prevent the worsening of the clinical picture, the spread of the
disease and the death of the patient [9]. This chapter will present molecular techniques applied
to the diagnosis of infectious disease of viral etiology and incidence worldwide. A critical first
step to proper treatment and control of any virus infection is a correct diagnosis. Conventional
diagnostic tests for viruses it based on amplification of conserved portions of the viral genome,
detection of antibodies against to viral proteins, or replication of the virus in cell cultures.
2. Dengue virus
Dengue virus (DENV) infection is the most common arthropodborne viral disease of humans;
Aedes mosquitoes, principally Aedes aegypti, transmit this disease. According World Health
Organization DENV is an emerging infectious agent that infects with an estimated 50–100
million clinical infections occurring annually worldwide [10]. DENV belongs to the family
Flaviviridae, genus Flavivirus. DENV is a small are spherical and enveloped virus that contain
a positive strand RNA genome of approximately 10,600 nucleotides coding for three structural
proteins (capsid C, membrane, M, and the envelope, E) and seven non-structural proteins (NS1,
xlinkA, xlinkB, NS3, NS4A, NS4B, NS5) [11], (Figure 1). The envelope protein (E) plays a key
role in several important processes including receptor binding, blood cell hemagglutination,
and induction of a protective immune response, membrane fusion and virion assembly. Two
types of virions are recognized: mature extracellular virions contain M protein, while imma‐
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ture intracellular virions contain prM, which is processed proteolytically during maturation
to yield M protein. The envelope of the virus contains the viral surface proteins E and M [12,13].
Figure 1. Schematic diagram of dengue virus genome. The DENV genome of positive-sense RNA and single-stranded,
comprises approximately 10,600 nucleotides. Any region of genome can be used for genome detection by molecular
techniques.
There are 4 antigenically and genetically distinct serotypes (DENV-1,-2,-3 and-4), being the
“Asian” genotypes of DEN-2 and DEN-3 the most frequently associated with severe disease
accompanying secondary dengue infections [14]. In human, the virus can cause a spectrum of
illness, 75% of DENV infections are asymptomatic. But in persons with symptomatic DENV
infection (dengue), the illness occurs in three phases. Acute phase, with 2–7 days of fever or
self-limiting influenza-like illness (dengue fever or DF), accompanied by headache, retro-
orbital eye pain, joint pain, muscle and/or bone pain, rash, mild bleeding manifestations and
low white cell count. The critical phase of dengue which marks a 24 to 48 hours, period in
which can occur the named severe dengue associated with vascular leakage, hemorrhage
(dengue hemorrhagic fever or DHF), potentially leading to vascular shock (dengue shock
syndrome or DSS), without appropriate treatment, patients with severe dengue are at risk of
death. The convalescent phase of dengue lasts for 4-7 days [15-18]. During the past five decades,
the incidence of dengue has increased 30-fold. In 2012, dengue was the most important
mosquito-borne viral disease in the world. The emergence and spread of all four dengue
viruses (“serotypes”) from Asia to the Americas, Africa and the Eastern Mediterranean regions
represent a global pandemic threat. Because epidemics of dengue result in human suffering,
strained health services and massive economic losses, an international effort to reduce
morbidity and mortality is long overdue coordinated by WHO named Global Strategy for
Dengue Prevention and Control 2012-2020 [19]. The goal of the global strategy is to reduce the
burden of dengue by to reduce mortality and morbidity from dengue by 2020 by at least 50%
and 25% respectively. The laboratory diagnosis of dengue can detect severe cases, case
confirmation and differential diagnosis with other infectious diseases. Diagnosis of dengue is
made by detecting the infective virus, virus genome, dengue antigen or by analyzing, the
serological responses (IgM or IgG) present after infection. Serology is currently the most widely
applied in routine diagnosis [20] (Table 1). After the mosquito bites occurs an incubation period
of 4–10 days, resulting in an asymptomatic or symptomatic dengue infection. In this period,
the virus replicates and an antibody response is developed (Figure 2). The development of IgM
antibody is coincident with the disappearance of fever and viraemia. In a primary infection
(when an individual is infected for the first time with a flavivirus), viraemia develops from 1–
2 days before the onset of fever until 4–5 days after and anti-dengue IgM specific antibodies
can be detected 3−6 days after fever onset. Low levels of IgM are still detectable around one to
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three months after fever. In addition, the primary infection is characterized by slowly increas‐
ing but low levels of dengue-specific IgG, becoming elevated at days 9−10. Low IgG levels
persist for decades, an indication of a past dengue infection. In a secondary infection, there is
a rapid and higher increase of anti-dengue specific IgG antibodies. High IgG levels remain for
30–40 days [21]. The serological tests have been used for the diagnosis of dengue infection:
hemagglutination-inhibition (HI), complement fixation (CF), neutralization test (NT), immu‐
noglobulin M (IgM) capture enzyme linked immunosorbent assay (MAC-ELISA) and indirect
immunoglobulin G ELISA. High cross-reactivity was observed with these tests. MAC-ELISA
and rapid tests are the most frequent methods for IgM detection and in the detection of IgG
are used HIA or ELISA [22-25]. Dengue non-structural protein 1 (NS1) is secreted from infected
cells and produces a very strong humoral response. NS1 is a useful early serum marker for
primary and secondary dengue infections, and is typically present between days 1–9 after onset
of clinical signs [23]. In febrile patients, the early diagnosis of dengue virus infection on based
on NS1 viral antigen [26-27]. At the end of the acute phase of infection, serology is the method
of choice for diagnosis by detection anti-DENV IgM and IgG antibodies using MAC-ELISA.
High sensitivity for NS1 antigen detection was observed by the association of MAC-ELISA
with a commercial anti-DENV IgM/IgG rapid test (PanbioH Dengue Early Rapid test) [28]. A
DENV NS1 capture assay using a test NS1 Ag Strip (BioRad Laboratories) is a valuable tool to
postmortem dengue confirmation [29]. There are several commercial kits to dengue diagnostic
such as the SD Bioline Dengue Duo device (Standard Diagnostic Inc., Korea) this test is
composed of 2 tests to detect DENV NS1 antigen (first test) and anti-DENV IgM/IgG (second
test) in serum, plasma or whole blood. With this test, still after the onset of illness, the virus
can detected in serum, plasma, circulating blood cells and other tissues for 4-5 days.
SAMPLE DIAGNOSTIC METHOD METHODOLOGY
Serological
response
Paired sera (acute serum
from 1-5 days and
second serum 15-21
days after)
IgM or IgG seroconversion ELISA
HIA
Neutralization test
Serum after day 5 of
fever
IgM detection (recent
infection)
ELISA
Rapid tests
IgG detection IgG ELISA
HIA
Virus detection
and its
components
Acute serum
(1-5 days of fever) and
necropsy tissues
Viral isolation Mosquito cell culture inoculation
Nucleic acid detection RT-PCR and real time RT-PCR
Antigen detection NS1 Ag rapid tests
NS1 Ag ELISA
Immuno-histochemistry
ELISA (Enzyme-linked immunosorbent assay). HIA (Haemagglutination inhibition assay). IgG (Immunoglubulin G). IgM
(Immunoglobulin M). NS1 Ag (Non-structural protein 1). RT-PCR (Reverse transcriptase polymerase chain reaction). In‐
formation based on Chapter 4. Laboratory Diagnosis and Diagnostic Tests. Dengue Guidelines for Diagnosis, Treat‐
ment, Prevention and Control. Geneva. TDR/World Health Organization. 2012 [21].
Table 1. Dengue diagnostic methods.
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Dengue diagnosis also relies on viral cell culture methods [30,31]. Specimens for virus isolation
should be collected early in the course of the infection, during the period of viraemia (usually
before day 5). Virus may be recovery from serum, plasma and peripheral blood mononuclear
cells. Dengue virus is heat-labile; specimens awaiting transport to the laboratory should be
kept in a refrigerator or packed in wet ice. Cell culture is the most widely used method for
dengue virus isolation usually takes several days. Four methods of viral isolation have been
routinely used for dengue viruses: intracerebral inoculation of newborn mice, inoculation on
mammalian cell cultures, intrathoracic inoculation of adult mosquitoes, and inoculation on
mosquito cell cultures [32]. The mosquito cell line C6/36 (cloned from Ae. albopictus) or AP61
(cell line from Ae. pseudoscutellaris) are the host cells of choice for isolation of virus. Indirect
fluorescent antibody staining of the infected cell culture is often regarded as the “gold
standard” in dengue diagnostics. However, it is tedious, time-consuming, and requires cell
culture. All these studies have shown that this can be a valuable approach, especially in the
early phase of infection; however, in some cases, they do not identify the viral serotype and
these assays may not be as sensitive as the detection of viral RNA by nucleic acid amplification
tests (NAAT) using reverse transcriptase-polymerase chain reaction (RT-PCR) and real-time
RT-PCR may assume a very important role in dengue diagnosis at confirms an acute dengue
infection [33, 20, 21]. Molecular diagnosis methods are usually rapid, sensitive, and simple
when correctly standardized and can be used for serotype identification and quantification of
genome copies in human clinical samples, biopsies, autopsy tissues, or mosquitoes. NAAT
assays may identify viral RNA within 24–48 hours. Although, also be able to detect dengue
viruses up to the 10th day after the onset of the symptoms. RNA extraction from clinical
samples can be performed with the QIAamp Viral RNA kit [34], VERSANT Molecular System
SP (Siemens) or HighPureViral Nucleic Acid Kit (Roche). Several RT-PCR procedures to detect
and identify dengue serotypes in clinical specimens have been reported such as one-step, two-
step, nested RT–PCR or real time RT–PCR [35]. These PCR assays vary in the amplified gene
regions of the genome, in the detection method of RT-PCR products, and the virus typing
methods. Real-time RT-PCR assays “singleplex” or “multiplex” can identify all four serotypes
from a single sample, in a single reaction and is useful to determine viral titer in a clinical
sample. Real-Time-PCR detection and typing of DENV usually addresses to the partially
conserved 3’-UTR region of the genome. Due to the typical RNA-viral sequence variations it
is difficult to identify one particular probe to be strictly related to one type or which could be
used for a melting curve based analysis [36].
Many laboratories utilize a nested RT-PCR assay, using universal dengue primers targeting
the C/prM region of the genome for an initial reverse transcription and amplification step,
followed by a nested PCR amplification that is serotype-specific. The analysis of the amplifi‐
cation efficiencies of an in-house quantitative real time-PCR (qPCR) assay of DENV, between
the region protein-5 (NS5) versus the capsid/pre-membrane region (C-prM) and the 3'-
noncoding region (3'NC) showed that the non-structural conserved genomic region the NS5
genomic region provides the best genomic region for optimal detection and typification of
DENV in clinical samples [37]. A fragment located at the 5’-UTR region of the virus genome
was successfully used to identify and quantify distinct dengue virus strains and serotypes in
clinical samples, in sera from patients infected with dengue virus, and in the mosquito Aedes
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aegypti, as well as to study virus replication in different cell lines using TaqMan probes [38].
A real time RT-PCR (qRT-PCR) for DENV using TaqMan Minor Groove Binding (MGB) probe
approach was development for detection and quantitation of all four serotypes using a single
probe primer set targeted against the 3'UTR of DENV. In this assay, the limit of detection was
DENV-1 (0.98 UFP/ml), DENV-2 (0.99 UFP/ml), DENV-3 (0.99 UFP/ml) and DENV-4 (0.99
UFP/ml) [39]. Other option to diagnosis to provide serotype specificity is a multiplex rRT-PCR
assay targeting the 5’ untranslated region and capsid gene of the DENV genome using
molecular beacons. This assay was linear from 7.0 to 1.0 log10 cDNA equivalents/mL for each
serotype. The limit of detection was calculated to be 0.3 cDNA equivalents/mL for DENV-1,
13.8 for DENV-2, 0.8 for DENV-3, and 12.4 for DENV-4 [40]. A technique for the multiplex
detection and typing of all DENV serotypes from clinical samples is PCR-ligase detection
reaction (LDR). In this technique, a serotype-specific PCR amplifies the regions of genes C and
E simultaneously. Then, two amplicons are targeted in a multiplex LDR, and the resultant
fluorescently labeled ligation products are detected on a universal array. The sensitivity of the
assay was 98.7%, and its specificity was 98.4%, relative to the results of real-time PCR. The
detection threshold was 0.017 PFU for DENV-1, 0.004 PFU for DENV-2, 0.8 PFU for DENV-3,
and 0.7 PFU for DENV-4. The assay is specific; it does not cross-react with the other flaviviruses
tested (West Nile virus, St. Louis encephalitis virus, Japanese encephalitis virus, Kunjin virus,
Murray Valley virus, Powassan virus, and yellow fever virus). The detection limit of the assay
ranged from 0.004 to 0.7 equivalent PFU/reaction. The assay was 100 times more sensitive for
DENV-2 and DENV-1 (LOD, 0.004 and 0.017 equivalent PFU, respectively) than for the others
serotypes [41]. Detection of DENV in urine is other diagnostic method, a study by real-time
RT-PCR, reported the detection of viral genome in urine between days 6 to 16[42]. Recently,
CDC development a CDC DENV-1-4 Real-Time RT-PCR Assay, the first molecular test
Figure 2. Immune response to virus dengue. In the infection course of dengue virus, the host’s B cells produce IgM
and IgG antibodies, which are released for recognize and neutralize the dengue virus and molecules such as the den‐
gue NS1 protein with the purpose of eliminates the virus. The figure shows the viremia can detect by the amplification
of the NS1 gene by RT-PCR and the antibodies titers by ELISA. Information based on Guzman MG, et al., 2010 [25] and
WHO, Geneva, 2009 [10].
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approved by the US Food and Drug Administration (FDA) for the identification of dengue
virus serotypes 1, 2, 3 or 4 from viral RNA in serum or plasma (sodium citrate) collected during
the acute phase. The limit of detection (LoD) of assay was determined to be between 1 x 104
and 1 x 103 GCE/mL for all serotypes in both formats in serum and plasma [43]. In all reactions
by real-time RT-PCR, a positive PCR result is a definite proof of current infection and it usually
confirms the infecting serotype. However, a negative result is interpreted as "indeterminate".
Patients receiving negative results before 5 days of illness are usually asked to submit a second
serum sample for serological confirmation after the 5th day of illness. Also, it was used other
options to diagnostics dengue infection. The first is Virochip is a pan-viral microarray platform;
this assay can detect to virus of Herpesviridae, Flaviviridae, Circoviridae, Anelloviridae,
Asfarviridae, and Parvoviridae families. In other hand, for viral detection exists the option
Deep sequencing and shotgun sequencing of human clinical samples by pyrosequencing using
the Illumina GAII platform [44].
3. Influenza virus
Influenza is a highly contagious respiratory disease of humans, with propensity for seasonal
epidemics and occasional pandemics. This disease constitutes a global health issue, leading to
morbidity, mortality, and economic losses. During influenza season, influenza viruses
circulate ubiquitously in the population. Global influenza surveillance forms the primary line
of defense against the occurrence of influenza pandemics by identifying emerging influenza
virus strains that pose a potential threat [45]. Influenza affects all age groups that result from
its pulmonary complications. The virus initially infects the upper airways but can directly
extend to the lower airways in severe cases, resulting in a viral pneumonia with significant
morbidity and mortality [46, 47]. Influenza viruses belong to the Orthomyxoviridae family and
are organize into types A, B and C. Influenza types A and B are responsible for epidemics of
respiratory illness in humans and animals. The etiologic agent of influenza is the influenza
virus with negative-strand, segmented RNA genome. Influenza type A and B viruses have 8
genes that code for 10 proteins. The virion has two surface glycoproteins (hemagglutinin (HA)
and neuraminidase (NA) and the M2 protein protrude through envelop (Figure 3). Influenza
virus binds to its sialic (neuraminic) acid receptor on respiratory epithelial cells by means of
the HA protein [48]. The influenza type A viruses are sub classified into different subtypes
according to HA and NA proteins, there are 16 HA subtypes and 9 NA subtypes, all of them
have been identified and isolated from birds, humans and can affect a range of mammal
species. The influenza A subtypes that circulated extensively in humans are A(H1N1);
A(H1N2); A(H2N2); and seasonal influenza A (H3N2) [49]. Influenza A viruses (IAV) are the
cause of pandemics, which are generated by the rearrangement (reassortment) of viral RNA
segments in cells infected with two different viral strains [50].
Pandemic viruses of influenza A virus including “Spanish influenza” (H1N1 in 1918) and A/
H1N1 or A(H1N1)pdm09 (H1N1 in 2009) [51] or rarely, a novel influenza A virus infection.
For the diagnosis, the influenza tests that provide accurate and timely results are the most
recommended. The appropriate respiratory samples for influenza testing are upper respiratory
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tract specimen such as deep nostrils (nasal swab), throat (throat swab) and nasopharynx
(nasopharyngeal swab). Nasopharyngeal aspirate and bronchial aspirate are also useful.
Samples should be collected within the first 4 days of illness [52,53]. According to WHO the
diagnosis of influenza is based in enzyme-linked immunosorbent assay (ELISA), haemagglu‐
tination inhibition (HI) and neuraminidase inhibition (NI) tests, egg and cell culture inocula‐
tion, and conventional reverse transcriptase PCR (RT-PCR) and Real-Time PCR (Table 2). The
reference standards for laboratory confirmation of influenza virus infection are reverse
transcription-polymerase chain reaction (RT-PCR) or viral culture [54]. Serologic testing is
usually not recommended to detect evidence of human influenza virus infection for manage‐
ment of acute illness. However, a variety of serological tests, including the hemagglutination
inhibition (HAI) test, complement fixation and EIA are used for testing paired acute and
convalescent phase sera to detect antibody titers. The Rapid Influenza Diagnostic Tests (RIDTs)
can identify the presence of influenza A and B viral nucleoprotein antigens, the result only is
positive or negative. The RIDTs are immunoassays than provide results in 10–30 min but
exhibit decreased sensitivity (70%–90% in children and 40% to 60% in adults), compared with
RT-PCR and with viral culture. There is a potential for false negative results. Negative results
of RIDTs do not exclude influenza virus infection in patients with signs and symptoms
Figure 3. Schematic representation of influenza virus A (not drawn to scale). On the envelope viral are anchored: HA,
M2 (ion channel protein) and NA protein. Inside the virion the negative-RNA single-stranded and segmented viral ge‐
nome with ARN polymerase formed for PB1, P2 and PA. Also, there is a NEP protein.
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suggestive of influenza, follow-up testing with RT-PCR and/or viral culture should be
considered to confirm negative test results [55]. Besides, of its low sensitivity RIDTs may be
used to help with diagnostic and treatment decisions for patients in clinical settings, such as
whether to prescribe antiviral medications [45]. These tools are continuously improved, a
double-sandwich ELISA (pH1N1 ELISA), based on two monoclonal antibodies against
haemagglutinin (HA) of the pH1N1 virus has a sensitivity of 92.3% (84/91, 95% CI 84.8–96.9%),
being significantly higher than that of the BD Directigen EZ Flu A+B test (70.3%, p <0.01). In
addition, this assay can directly differentiate pandemic (H1N1) 2009 (pH1N1) virus from other
respiratory pathogens, including seasonal influenza virus [56]. A hemagglutination inhibition
assay is an extremely reliable tool for typing, subtyping and analyze the antigenic character‐
istics of influenza viral isolates if the reference antisera used contain antibodies to currently
circulating viruses [53]. An HAI test showed that the patients with influenza A H1N1 have
effective immune response [57]. The Directigen EZ Flu A+B test is a rapid chromatographic
immunoassay for the qualitative detection of influenza A and B viral antigens, it has an
accuracy of 95.5% and 96.8%, respectively. This kit has the ability to detect H5N1 isolates and
of the A/California/07/2004 strain [BD Diagnostics, Becton Dickinson and Company, 2005].
Viral culture is considering one “gold standard” for detection of infection with human
influenza viruses. Although, viral isolation is not a screening routine test in outbreaks, during
periods of low influenza activity, could performed on respiratory specimens collected from
persons with suspected influenza. Viral culture does not provide timely results (1-14 days) [58,
59]. In the influenza seasonal and in outbreaks, the viral culture is essential as a source of
virologic data about strain characteristics, such as antigenic comparison to influenza vaccine
strains and antiviral susceptibility that are important for clinicians and public health. Shell vial
centrifugation cultures have been used to shorten the time to results to 1 to 5 days, to detect
viral antigens [60]. Immunofluorescence using direct fluorescent antibody or indirect fluores‐
cent antibody staining for influenza antigen detection are used as screening tests. This test
exhibits slightly lower sensitivity and specificity than viral isolation in cell culture, but results
are obtained within hours [45]. An example is the Respiratory Screen direct immunofluores‐
cence antibody (DFA) (direct fluorescent antibody) staining of cells collected using nasophar‐
yngeal (NP) swabs or NP aspirates can detects not only influenza, but RSV, parainfluenza types
1,2,3, and adenovirus. DFA is reported within 2-3 hrs [61]. However, for detection of respira‐
tory viruses in clinical specimens, the nucleic acid tests (NATs) are fast, accurate and sensitive
test. Several nucleic acid based amplification approaches have been applied for the detection
of individual respiratory viruses including PCR, nucleic acid sequence-based amplification
(NASBA), loop mediated isothermal amplification (LAMP), and multiplex ligation-dependent
probe amplification (MLPA) [62-65]. For NATs, the nucleic acid is extracted from the samples
by using commercial kits, like QIAamp viral RNA extraction kit (Qiagen, Hilden, Germany)
using silica gel membrane technology. KingFisher mL (ThermoFisher Scientific Inc., Worces‐
ter, MA, USA) and easyMAG (bioMérieux, Marcy l’Etoile, France) kits using magnetic beads-
based technology [66, 67]. TruTip (Akonni Biosystems, Inc., Frederick, MD, USA) use a porous
nucleic acid binding matrix embedded within a pipette tip [68]. Reverse transcriptase-PCR
(RT-PCR) or Real-time RT-PCR can be considered the other “gold standard” for detection of
influenza viruses due to its high sensitivity and specificity for detection of influenza A and B
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viruses. The results are available within 4–6 h after specimen submission. These molecular
tools are used as a confirmatory test. Several different gene targets have been used for
amplification such as the matrix (m) to detect all influenza A subtypes, ha to distinguish
between influenza A, B and C or between influenza A subtypes and non-structural protein
genes (nsp) [69-71]. In all eight segments of influenza A virus, the first 12 nucleotides of the 3′
terminus (Uni12) and the first 13 nucleotides of 5' terminus (Uni13) are conservative and are
the target to designed a primers pair. Detection of influenza A virus in human nasal swabs can
performed by RT-PCR with Uni12 and Uni13 primers. The coupling of RT-PCR with sequenc‐
ing analysis provides information about viral genotype [72]. Multiplex RT-PCR assays have
been widely used for detection and differentiation of a panel of respiratory viral pathogens.
FluPlex is a multiplex RT-PCR enzyme hybridization assay, capable of typing influenza viruses
and subtyping HA (H1, H2, H3, H5, H7, and H9) and NA (human N1, animal N1, N2, and N7)
with high sensitivity (10–100 copies/reaction) [73]. As the Qiagen ResPlex II multiplex RT-PCR
kit, an test with high specificity for detection of 17 viral pathogens in nasopharyngeal swab
samples such as influenza A virus (FluA), FluB, FluA 2009 pandemic A(H1N1)pdm09 and
others pathogens as parainfluenza virus 1 (PIV1), PIV2, PIV3, PIV4, respiratory syncytial virus
(RSV), human metapneumovirus (hMPV), rhinoviruses (RhV), adenoviruses (AdV), four
coronaviruses (229E, OC43, NL63 and HKU1) [74]. The TrueScience RespiFinder Identification
Panels (Applied Biosystems) is other multiplex PCR test to detect and differentiate 15 respi‐
ratory pathogens, using the multiplex ligation-dependent probe amplification (MLPA)
technology, which starts by a preamplification step, which ensures the detection of both RNA
and DNA viruses.
Follow is performed a reverse transcription, a PCR reaction, the hybridization probes to their
target regions to the PCR product. A ligation probes and the final PCR exponentially amplifies
the ligated probes with only two primers. The targets are detected through capillary electro‐
phoresis. The pathogens potentially identified are Influenza A, Influenza B, Influenza A H5N1,
Parainfluenza 1, Parainfluenza 2, Parainfluenza 3, Parainfluenza 4, RSV-A, RSV-B, Corona
229E, Corona NL63, Corona OC43, Adenovirus, Rhinovirus, Bordetella pertussis, Chlamydo‐
phila pneumoniae, Legionella pneumophila and Mycoplasma pneumoniae. MPLA shows
specificities and sensitivities of 98.2% and 100%, respectively, for influenza A virus [75]. A
successful test to detect a H5N1 virus was based on Loop-Mediated Isothermal Amplification
(LAMP) method. For other side, detection, quantification and subtyping of influenza viruses
can be performed by real-time RT-PCR (qRT-PCR). There are many papers of this technique
applied to influenza A diagnosis such as TaqMan qRT-PCR method, which detects HA and
NA genes of HPAI H5N1 virus [76]. A new generation qRT-PCR approach designated as Super
high-speed qRT-PCR (SHRT-PCR) is a version of qRT-PCR with an extremely short reaction
time (less than 20 min per run for 40 cycles) capable to detects viral RNA segments of influenza
A [77]. RealTime ready Influenza A/H1N1 Detection Set (Roche) is an assay to detect the M2
gene (M2 PCR) of a generic influenza virus A and a specific PCR targeting the HA of A/H1N1-
pdm09 (HA PCR, 2009 H1N1), to detect and quantify the 2009 H1N1 virus in clinical samples
[78]. CDC developed the CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel-
Influenza A/H7 (Eurasian Lineage) assay for patients with signs and symptoms of respiratory
infection. The kit contains a dual-labeled hydrolysis probe (TaqMan). The limit of detection of
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this kit was 103.4 [79]. On April 1, 2013, an outbreak of human infections with a new avian
influenza A (H7N9) virus was first reported in China by the World Health Organization. The
diagnostics of this virus used the real time RT-PCR by TaqMan assay. Other molecular
technique to diagnosis is DNA microarray such as FluChip-55 [Sakurai & Shibasaki, 2012] used
METHOD TYPE INFLUENZA VIRUS TYPE SPECIMENS
Cell culture (Madin-Darby canine kidney
(MDCK), mink lung epithelial cell line
(Mv1Lu), rhesus monkey kidney (LLC
MK2), and buffalo green monkey kidney
(BGMK)
A and B NP swab, throat swab, NP or bronchial
wash, nasal or endotracheal aspirate,
sputum
Rapid cell culture (commercial shell vials,
single or mixed cell lines)
A and B NP swab, throat swab, NP or bronchial
wash, nasal or endotracheal aspirate,
sputum
Immunofluorescence microscopy by
direct fluorescent antibody (DFA) test or
an immunofluorescent antibody (IFA)
test, using commercial monoclonal
antibody for influenza A and B viruses; or
non commercial monoclonal antibody
specific for H1, H3 H5, H7 and H9
A and B
Identification of subtypes of A
NP swab, thrat swab, NP or bronchial wash,
NP or endotracheal aspirate, sputum
Immunospecific assay for viral antigen
detection
Rapid influenza diagnostic test (RIDT’s)
A and B NP swab, nasal wash, NP aspirate, throat
swab
Viral antibody detection
Virus neutralization test
Haemmaglutination inhibition
ELISA using commercially anti-human
antibody conjugates
Complement fixation
A and B Serum
Nucleic acid testing (Conventional RT-
PCR singleplex and multiplex, Multiplex
PCR, Degenerate PCR, Probe-based real-
time PCR (TaqMan), SBRY Green I-based
real-time PCR, Microarrays, NABA, LAMP,
Pyrosequencing
A and B
Identification of subtypes of A
NP swab, throat swab, NP or bronchial
wash, NP or endotracheal aspirate, sputum
Information based on Centers for Disease Control and Prevention, National Center for Immunization and Respiratory
Diseases (NCIRD). Guidance for Clinicians on the Use of Rapid Influenza Diagnostic.2011. Petric M, et al. 2006 [64];
Wang&Taubenberger, 2010 [65].
Table 2. Methods of diagnosis of influenza virus.
Molecular Diagnostics as an Indispensable Tool for the Diagnosis of Infectious Diseases of…
http://dx.doi.org/10.5772/57581
99
in influenza diagnosis and others viruses such as parainfluenza, respiratory syncytial virus,
human metapneumovirus, adenovirus, rhrinoviruses, coronaviruses causes pneumonia,
which can be analyzed by multiplex PCR that assist in the discrimination of the etiologic agent
[Pavia, 2011; Mahony, 2008]. The NGEN respiratory virus analyte-specific assay (Nanogen,
San Diego, CA) detects influenza A, influenza B and others pathogens such as PIV type 1
(PIV-1), PIV-2, PIV-3, and RSV on a NanoChip 400 electronic microarray. The FilmArray
Respiratory Panel (RP) is a PCR array test (Idaho Technology, Inc., Salt Lake City, UT) that can
detect up to 21 viral and bacterial respiratory pathogens within about an hour as Adenovirus,
Bocavirus, Coronavirus 229E, Coronavirus HKU1, Coronavirus NL63, Coronavirus OC43,
Human Metapneumovirus, Parainfluenza virus 1, Parainfluenza virus 2, Parainfluenza virus
3, Parainfluenza virus 4, Rhinovirus/Enterovirus, Respiratory Syncytial Virus, Bordetella
pertussis, Chlamydophila pneumoniae, and Mycoplasma pneumonia and Influenza A,
Influenza A subtype H1, Influenza A subtype H3, Influenza A subtype H1 2009, Influenza B.
This assay is a feasible alternative to viral culture in an acute clinical setting [80]. Recently, it
was reported the method for the detection of genetic markers associated with high pathoge‐
nicity of influenza virus [81].
4. Human papillomavirus
Human papillomavirus (HPV) is a pathogen associated to development of cervical cancer,
which is the second more common cancer in women worldwide. These viruses typically infect
the skin and mucosal surfaces of humans. HPV is a non-enveloped virus with a circular and
supercoiled double-stranded DNA genome of approximately 8,000 bp long within an icosa‐
hedral coat or capsid comprised by 72 pentameric capsomers. The open reading frames (ORFs)
in the viral genome are organized in three regions: the early expression region (E), the late
region (L) and the long control region (LCR) that bears the origin of viral replication and
transcription. The E region codes for proteins related to replication (E1) and to activation or
repression of the viral DNA (E2), and the oncogenes E6, E7, E5 [82]. The L1 and L2 genes encode
the mayor and minor capsid proteins. Late genes L6 and L7 code for structural capsid proteins
which encapsidate the viral genome (Figure 4) [83]. The L1 gene is the region most conserved
between individual types and used to analyze phylogenetic relationship.
Those HPVs with L1 sequence divergence of 2–10% are known as subtypes and less than 2%,
variants. The term “genus” is used for the higher order clusters, named using the Greek
alphabet, and within genus, small clusters are referred to as species and given a number
[84-86]. There are more than 200 different types, of which approximately 100 are fully se‐
quenced and classified according to their biological niche, phylogenetic position and oncogenic
potential [87]. About 40 can infect the anogenital mucosa of humans (mucosotrophic HPVs)
[88-89]. According to their association with cervical cancer, there are low-risk HPV, which can
cause benign or low-grade cervical cell changes, genital warts, and recurrent respiratory
papillomatosis. High-risk HPV types act as carcinogens in the development of cervical cancer
and other anogenital cancers [90]. Cervical cancer is a commonly-encountered malignant
tumor in women. The surveys demonstrated that the increase of women with cervical cancer
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less than 35 years old is particularly significant. The possible causes that result in cervical
cancer to tend to occur in young include remarkable increase of HPV infection rate, especially
the high-risk HPV 16 and 18 infection closely related to cervical cancer [91]. The primary
screening and diagnostic methods have been cytology and histology. Papanicolaou (Pap)
staining is the gold standard for detecting abnormal cervical epithelial cells, using microscopic
analyses of conventional cervical smears or cell suspensions from liquid cytology medium.
The limitation of Pap smear are low specificity, is need repeat the screening at short intervals
[92]. Morphological findings from a cytology analysis determine the level of risk for develop‐
ing cervical malignancies. Cervical epithelial cells atypical or abnormal are known as “atypical
squamous cells of undetermined significance” (ASCUS). Some ASCUS signals the presence of
low-grade squamous intraepithelial lesions (LSIL). However, some ASCUS are associated with
underlying high-grade disease, including cervical intraepithelial neoplasia (CIN) [93-95]. HPV
serology is not used diagnostically. Detection of the humoral antibody response is type-specific
and first detected 6–18 months after infection. The response is weak and only between 50–60%
of patients positive to HPV DNA-positive mount a measurable antibody response [96].
Although, the role played by the humoral immune response during the HPV infection is not
very well understood; it was observed that this response is generated all throughout the
malignant process; 54%-69% of women with incident HPV 16, 6, or 18 infections had antibod‐
ies. Serum antibodies against many different viral products of HPV have been detected by
ELISA. The best characterized and most type-specific antibodies are those directed against
conformational epitopes of the L1 capsid protein assembled as VLPs (virus-like particles) such
as HPV-16 L1 VLP (virus-like particle)-based ELISA [97]. There is some high-throughput
single-serum-dilution enzyme-linked immunoassay (ELISA) system for determining anti-
HPV antibody titers following vaccination against HPV [98].
At present there is no “gold standard” for HPV detection. Guidelines for the management of
women with cervical neoplasia or abnormal cervical cancer screening tests indicates the
immediate colposcopy (cervical exam), cytologic follow-up, and triage by HPV DNA testing
Figure 4. Linear representation of Human Papillomavirus (HPV) genome. The circular HPV genome has approximately
7900 base pairs, in the schematic with eight overlapping reading frames. L1 is signaled as the most used genomic tar‐
get for detection of HPV.
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[99]. HPV serves as paradigm for the use of NAATs due to how difficult it is to obtain the virus
via cell cultures or to develop indirect diagnosis techniques [100]. There are several molecular
techniques for HPV DNA detection (Table 3). They include DNA hybridization, PCR-RFLP,
reverse-line hybridization and hybrid capture assay. The method most commonly used is the
polymerase chain reaction (PCR). All target amplification techniques such as PCR for HPV
virus detection currently use consensus or type-specific primers group-or type-specific
conventional PCR, to amplify a broad-spectrum of HPV genotypes by targeting a conserved
region within the HPV genome [101, 102]. L1 and E1 regions are the most conserved parts of
the genome [103]. Many assays use primers targeted to the viral capsid L1 gene, which can
detect numerous HPV types [104]. There are several PCR primer sets as GP5+/6+that amplify
a 140 bp region in the L1 gene allowing the identification of 30 HPV genotypes. This method
is useful in predicting high-grade cervical intraepithelial neoplasia. The MY09/11 system
identifies high-risk HPV genotypes by amplifying a 450 bp sequence in the conserved L1
region. The MY09/11 primer set uses degenerate bases to reduce variability due to different
genotypes. The SPF10 system primers amplify a 65 bp sequence from a highly conserved region
of the viral L1 gene for the identification of 16 different genotypes of the human papillomavirus
(HPV) [105]. Commonly used L1 consensus primer sets include PGMY09/11, GP5+/6+, and
SPF10, having the ability to identify a large range of HPV types with 1 amplification [106,
107]. Hybridization on PCR products (Cervista HPV HR Test, INNO-LiPa HPV Genotyping,
Linear Array HPV Genotyping Test, Digene HPV Genotyping RH Test) [Estrade et al., 2011;
Jeney et a., 2007; Chan et a., 2012]. Linear Array HPV Genotyping Test (Roche Diagnostics,
Indianapolis, IN) is able to identify 37 types of HPV, 14 are high-risk genotypes. Linear Array
also includes PGMY primers and is a commonly used method for genotyping HPV using
Probes for multiple HPV types are fixed on a membrane strip, and the PCR product is
hybridized to the strip, followed by visual detection [108]. Other assay so used is INNO-LiPA
HPV Genotyping Extra (Innogenetics, Ghent, Belgium). This kit amplifies HPV DNA with
SPF10 primers at the L1 region. The probes are fixed to membrane strips in sequence-specific
lines and visualized as purple/brown bands. The test can detect and distinguish 24 low-and
high-risk HPV types. [INNO-LiPA HPV Genotyping Extra. Ghent, Belgium: Innogenetics;
2007. A HPV viral target to detect is the L1 gene to amplify a broad spectrum of HPV types
with a single set of degenerated primers or a cocktail of primers (Amplicor HPV Test) [Sepehr
et al., 2012] and HPV mRNA amplification against HPV E6/E7 mRNA (APTIMA HPV Assay,
NucliSENS EasyQ HPV, PreTect HPV-Proofer). Another test is the Multiplex Genotyping Kit
(Multimetrix, Heidelberg, Germany). The test is a PCR-based fluorescent bead array that can
detect 24 low-and high-risk HPV types [109]. The quadruplex quantitative PCR method
(AllGlo fluorescent probes) was established to simultaneously detect and differentiate HPV 6,
11, 16 and 18 [110]. Between the signal amplification methods are liquid-phase or in situ
hybridization as Hybrid Capture 2 HPV DNA Test for to detect 13 high-risk types (HPV 16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68) and five low-risk types [111, 112]. Microarray on
PCR products is other molecular technique to detect influenza virus such as Infiniti HPV-HR
QUAD Assay, PapilloCheck or HybriMax for HPV genotyping [113]. PapilloCheck (Greiner
Bio-One, Monroe, NC) for HPV genotyping PapilloCheck identifies 24 types of low-and high-
risk HPV with a high specificity and sensitivity [114]. Genotyping with this method is based
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on PCR amplification of the E1 gene by a group of new E1-specific primers, followed by
hybridization to a DNA chip with immobilized HPV oligoprobes. A novel assay for molecular
diagnostics and typing application known as Sequencing Bead Array (SBA) is an alternative
method to HPV diagnosis. SBA is a digital suspension array using Next-Generation Sequenc‐
ing (NGS) that in the case of HPV could distinguish ten Human Papillomavirus (HPV)
genotypes associated with cervical cancer progression. This is a robust system capable to
identify genetic signatures or single nucleotide polymorphisms (SNPs). SBA has the potential
to change the probe-based diagnostics, and allow for a transition towards the technology by
genomic sequencing [115]. Some groups are studying other molecular factors as possible
markers of infection by HPV as a complementary diagnostics. The overexpression of the HPV
E6 and E7 genes is indicated in HPV-induced carcinogenesis, making these genes a potential
measure of virulence. Monitoring the expression levels of these genes may allow for screening
and monitoring of cancer progression [116].
MOLECULAR DIAGNOSIS
METHOD
NAME TEST GENOTYPES AND TARGET DETECTED
Real time Real Time High risk HPV test
(Abbott Molecular)
14 high risk HPV genotypes: 16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, 66, 68 and to partially genotype
16, 18 from other 12 high risk genotypes using L1
gene.
Cobas 4800 HPV Test
Amplification/Detection kit
(Roche Molecular Diagnostics)
HPV 16 and HPV 18 and concurrently detecting the
rest of the high risk types (31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66 and 68), using L1 gene
Hybrid capture Hybrid Capture 2 High-Risk HPV
DNA Test
High-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59 and 68 using all genome.
PCR and hybridization AMPLICOR Human
Papillomavirus Test (Roche
Molecular Diagnostics)
HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59 and 68 using L1 gene.
TMA APTIMA HPV assay
(Hologic)
Qualitative detection of E6/E7 viral messenger RNA
(mRNA) from 14 high-risk types of HPV: 16, 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
Reverse hybridization Digene HPV Genotyping RH Test
(Qiagen)
Detection of HPV subtypes 16, 18, 26, 31, 33, 35, 39,
45, 51, 52, 53, 56, 58, 59, 66, 68, 73 and 82 using L1
gene.
INNO-LiPA HPV Genotyping Extra
(Innogenetics)
Detection of at least 54 HPV types using L1 gene.
Linear Array HPV Genotyping test
(Roche Molecular Diagnostics)
Linear Array detects thirty seven anogenital HPV
DNA genotypes 6, 11, 16, 18, 26, 31, 33, 35, 39, 40,
42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66,
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MOLECULAR DIAGNOSIS
METHOD
NAME TEST GENOTYPES AND TARGET DETECTED
67, 68, 69, 70, 71, 72, 73 (MM9), 81, 82, 83, 84, IS39
and CP6108.
Invader chemistry Cervista HPV HR Test (Hologic) Detection of 14-type High Risk HPV genotypes: 16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 using
L1 gene.
PCR-microarray PapilloCheck HPV-Screening Test
(Greiner Bio-One)
Type-specific identification of 18 high-risk(16,18,
31,33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73,
82) and 6 low-risk types of HPV (6, 11, 40, 42, 43, 44)
using E1 gene.
Clart HPV 2
(Genomics)
Identification of HPV 6, 11, 16, 18, 26, 31, 33, 35, 39,
40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62,
66, 68, 70, 71, 72, 73, 81, 82, 83, 84, 85 and 89
genotypes using L1 gene.
Infiniti HPV Genotyping assay
(AutoGenomics)
Genotyping of HPV 6, 11, 16, 18, 26, 30, 31, 33, 34,
35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 69, 70,
73, 82 and 85 using E1 gene.
NASBA amplification and
real-time detection using
molecular beacon probes
NucliSENS EasyQ HPV
(BioMérieux)
Discriminates the E6/E7 mRNA between genotypes
16, 18, 31, 33 and 45.
Next-Generation assay NextGen HPV Screening Assay
and Platform (Qiagen)
15 high risk subtypes (+ types 66 and 82)
Information based on Kroupis C, et al., 2011 [90]; Arney A, et al., 2010 [100].
Table 3. Principal methods of molecular diagnosis of HPV.
Analysis of the host factor p16INK4a (p16), a cyclin-dependent kinase inhibitor could be a
molecular marker to HPV infection. The increase of p16 indicates removal of the negative
feedback control supplied by the retinoblastoma gene, pRB. When oncogenic HPV E7 proteins
bind to pRB, p16 is overexpressed and elevated, representing active expression of HPV
oncogenes [117]. The sialylation modification observed during oncogenic transformation,
tumor metastases and invasion, has been associated with enhanced sialyltransferases (STs)
transcription such as ST3Gal III, ST3Gal IV and ST6Gal I in CIN [118].
5. Viral hepatitis
Viral hepatitis is a necroinflammatory liver disease of variable severity. Persistent infection by
HBV is often associated with chronic liver disease that can lead to the development of cirrosis
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and hepatocellular carcinoma being a global public health as chronic diseases, cause of
infectious disease mortality globally, each year causing approximately 1.4 million deaths. In
addition, viral hepatitis are cause of liver cancer and the most common reason for liver
transplantation [119]. The viruses more common are Hepatitis A, Hepatitis B, and Hepatitis
C. Approximately 400 million persons living with chronic hepatitis B virus (HBV) or hepatitis
C virus infection who die from cirrhosis or liver cancer, years and decades after of their
infection [120]. Hepatitis B is caused by infection with HBV, which may lead to acute or chronic
hepatitis. HBV is the 9th leading cause of death worldwide. It causes cirrhosis, liver failure
and hepatocellular carcinoma. HBV is a small nonenveloped DNA virus that is a member of
the Hepadnaviridae family, HBV contains a 3.2-kb partially double-stranded DNA genome
with 4 open reading frames encoding 7 proteins (P/viral polymerase, S/Surface antigen
proteins/HBsAg, C/core protein, HBeAg y X/HBx protein) [121]. Eight genotypes of HBV
(designated-H) have been identified by sequence divergence of >8% over the entire genome
of HBV DNA [122]. HBV is efficiently transmitted by percutaneous or mucous membrane
exposure to infectious blood or body fluids that contain blood. Acute HBV infection can be
either asymptomatic or symptomatic. Symptoms in acute HBV infection are clinically indis‐
tinguishable from those in other acute viral hepatitis infections [123]. Diagnosis of hepatic viral
infection is carried out by studying biochemical as liver function tests, serologic assays and
histological parameters. Serological HBV diagnosis identifies virally-encoded antigens and
their corresponding antibodies in serum. Three clinical useful antigen-antibody systems have
been identified for hepatitis B: hepatitis B surface antigen (HBsAg) and antibody to HBsAg
(anti-HBs), antibody (anti-HBc IgM and anti-HBc IgG) to hepatitis B core antigen (HBcAg),
hepatitis B e antigen (HBeAg) and antibody to HBeAg (anti-HBe) [124]. B surface antigen
(HBsAg) is the first serological marker to appear during the course of HBV infection, is present
in both acute and chronic infection. The immunoassays to detect HBsAg are highly spectific
and show a sensitivity, allowing the detection of <0.15 ng/ml of HbsAg [125]. Detection of
HBsAg allowed for the first time screening of inapparently infected blood donors for a
dangerous pathogen. The simultaneous detection of antibodies against HBsAg (anti-HBs) and
HBcAg (anti-HBc) can be useful to know the evolution of disease. The presence of IgM antibody
to hepatitis B core antigen (IgM anti-HBc) is diagnostic of acute or recently acquired HBV
infection. Antibody to HBsAg (anti-HBs) is produced after a resolved infection and is the only
HBV antibody marker present after immunization. The presence of HBsAg and total anti-HBc,
with a negative test for IgM anti-HBc, indicates chronic HBV infection. The presence of anti-
HBc alone might indicate a false-positive result or acute, resolved, or chronic infection [126,
127]. Chronic HBV infection is defined by the persistence of serum HBsAg for more than 6
months [128]. Serologic assays for HBV are the mainstay diagnostic tools for HBV infection.
The clinically silent HBV infections are a strong driving force in the development of modern
virus diagnostics to analyze the HBV replication profile, HBV DNA levels and the viral protein
expression [129]. When serological testing could be inconclusive for the diagnosis of a HBV
infection (due to the presence of genetic variants of HBV), the molecular detection of HBV
DNA may help to resolve the uncertainties. The NAT assays in plasma or serum can detect to
10 copies/mL [130]. The viral genomes can be detected and quantified by polymerase chain
reaction (PCR), transcription-mediated amplification (TMA), and with signal amplification
Molecular Diagnostics as an Indispensable Tool for the Diagnosis of Infectious Diseases of…
http://dx.doi.org/10.5772/57581
105
methods such as hybrid-capture and the branched DNA assay. Quantification of genome of
HBV can be used for diagnosing HBV infection and monitoring the effect of antiviral therapy.
HBV DNA is the earliest detectable marker in acute HBV infection and the gold standard for
the diagnosis of occult HBV infection. HBV DNA testing is particularly useful in the detection
of the early phase of acute HBV infection prior to the appearance of serum HBsAg as well as
in occult HBV infection [131, 132]. Several commercial molecular assays have been developed
for quantitation of HBV DNA. Such as COBAS Amplicor HBV Monitor, which is based on the
amplification of DNA targets by PCR with HBV-specific primers. Between the hybridizations
methods are Hybrid capture Ultrasensitive hybrid capture II and Branched DNA VERSANT
hepatitis B virus DNA 3.0. Recently developed real-time target amplification methods have
improved viral genome detection and quantification for clinical and research purposes. Real
time PCR for HBV DNA has reached an excellent level of performance with a detection limit
close to the theoretical minimum of 1 DNA molecule per reaction mix and a huge dynamic
range up to 107 or more. In 1991 the WHO introduced International Standard preparations and
an arbitrary International Unit (IU) of HBV DNA. The number of molecules per IU depends
on the assay; but typically 5 molecules correspond to one IU HBV DNA [133]. Real-Time PCR
(Real Time Abbott PCR, Smart HBVTM, Real Art HBV, COBAS AmPliprep, Cobas TaqMan
HBV, Aptima HBV Quantitative assay) [134-136]. Fosun real-time PCR HBV kit is a comercial
assay for quantitation of serum HBV DNA based on TaqMan PCR technology, which is useful
for monitoring HBV DNA levels in patients with chronic hepatitis B. The limit of the duplex
real-time PCR assay was 29.5 IU/ml, whereas the specificity was 100% for the detection of HBV
DNA [137]. A trial has been tested, a TaqMan locked nucleic acid (LNA) real-time polymerase
chain reaction (PCR) probe for the accurate quantification and detection of hepatitis B virus
(HBV) DNA in serum (plasma) [138]. The genotyping analysis of HBV can performed by real-
time PCR using (GQ-PCR) method or the direct sequencing and reverse hybridization with
INNO-LiPA HBV genotyping assay [139]. Other option to diagnostics of hepatotrophic viruses
is Real-time PCR array, useful in the rapid detection of multiple viral pathogens, between them
hepatitis B virus (HBV), hepatitis C virus (HCV) using the SYBR Green chemistry. The array
detected: 10 genome equivalents (geq)/ml of HCV, 50 geq of HBV (genotype A) [140]. Micro‐
RNAs (miRNAs) are noncoding RNAs that regulate gene expression primarily at the post-
transcriptional level by binding to mRNAs. The circulating miRNA in serum or plasma might
be a very useful biomarker for the diagnosis and prognosis of HBV-related diseases, indicating
a promising future in the treatment of HBV-related diseases [141]. Hepatitis C virus (HCV) is
a major public health problem and a leading cause of chronic liver disease. An estimated 180
million people are infected worldwide, several of these patients go on to develop chronic HCV
infection, often developing into liver cirrhosis, hepatic failure and hepatocellular carcinoma
[142]. Hepatitis C virus is a single stranded RNA, enveloped virus, belongs to the Flaviviridae
family and is the only member of the Hepacivirus genus [143]. The commercially-available
diagnostic tests are based on enzyme immunosorbent assays (EIA) for the detection of HCV-
specific antibodies and recombinant immunoblot assays (RIBA). Although, in the diagnosis of
influenza is applied the algorithm showed in figure 5 [144-146]. Testing for circulating HCV
by genomic sequence amplification (PCR and branched DNA assay) has been successfully
utilized for confirmation of serological results and the effectiveness of antiviral therapy [134,
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147]. An alternative to HCV diagnosis is Loop-mediated isothermal amplification (LAMP)
assay for rapid detection of HCV genomic RNA [148]. The molecular HCV assays includes to
RT-PCR (AmpliScreen 2.0, Amplicor HCV 2.0, Cobas Amplicor Monitor HCV 2.0, Versant
HCV RNA, Procleix HIV/HCV assay, Procleix Ultrio assay). The methods for accurate
quantification of HCV RNA levels are key tools in the clinical management of patients. The
HCV RNA Assay by RT-PCR includes to Amplicor HCV Monitor 2.0, Cobas Amplicor Monitor
HCV 2.0, Cobas AmliPrep/Cobas TaqMan HCV, Versant HCV RNA 3.0 Quantitative assay,
LCx HCV RNA Quantitative assay, SuperQuant, Abbott RealTime [135]. To evaluate the
response to antiviral therapies is possible analyze the absence or alteration of genetic material
in clinical specimens from successfully treated patients. In situ hybridization (ISH) enables
visualization of specific nucleic acid in morphologically preserved cells and tissue sections.
The anti-sense probe detected HCV RNA, with a sensitivity and specificity of 95% and 100%,
respectively. HCV genomic RNA can be variably distributed in tissue sections and was located
primarily in the perinuclear regions in hepatocytes [149]. Viral hepatitis is one of the major
health problems worldwide. Hepatitis delta virus (HDV) is also not uncommon world-wide.
Hepatitis D virus (HDV) or delta virus is a defective virus. It requires the help of another virus
that is hepatitis B virus for its multiplication. It always occur with HBV either in the form of
co-infection or super-infection [150]. HCV, HBV, and HDV share parallel routes of transmis‐
sion due to which dual or triple viral infection can occur in a proportion of patients at the same
time. HBV and HCV are important factors in the development of liver cirrhosis (LC) and
hepatocellular carcinoma [151]. In the diagnosis of co-infections, individually each infection
(HBV, HCV and HDV) is confirmed by the presence of the serum surface antigen, hepatitis B,
C and D envelope antigen and specific antibodies to the hepatitis B, C and D core [152]. By
Deep Sequencing were readily detected at high coverage in plasma of patients with chronic
viral hepatitis B and C. Although, this protocol also is adapted to other samples such as urine,
bile, saliva and other body fluids by viral metagenomic survey [153]. For other side, other
molecular technique as the protein micro-array gives a way to diagnosis multiple viral
infections; using two viral antigens (HBsAg, HBeAg) and seven viral antibodies (HBsAb,
HBcAb, HBeAb, HCVAb, HDVAb, HEVAb, HGVAb) of human hepatitis viruses [154]. Finally,
the successful simultaneous detection of HAV, HBV and HCV was performed with the
Magicplex HepaTrio Real-time Detection test, whose sensitivity and specificity of the Hepa‐
Trio test were 93.8% and 98.2%, respectively, for detecting HBV infection, and 99.1% and
100.0%, respectively, for HCV infection [155].
6. Mumps virus
Mumps is an acute viral infection caused by a member of the Rubulavirus genus in the
Paramyxoviridae family. Mumps virus (MuV) is pleomorphic, enveloped, comprising a
nucleocapsid core with helical structure composed of the 15384 nucleotide. Nonsegmented
negative-sense RNA genome has the organization: 3′-NP-P-M-F-SH-HN-L-5′ [156]. The
molecular epidemiology of MuV is characterized by the co-existence of 10 (or more) distinct
genotypes named A-J based on the nucleotide sequence of the SH gene. MuV genotypes (C,
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D, H, J) and vaccine strains (Urabe Am9) have been associated with enhanced neurovirulence
[157]. MuV is known to affect the salivary glands causing parotid swelling lasting at least two
days, but may persist longer than ten days [158]. The mumps incubation period ranges from
12–25 days, but parotitis typically develops 16 to 18 days after exposure to mumps virus. The
MuV also produce an acute systemic infection involving glandular, lymphoid and nervous
tissues, leading to some important complications, the main central nervous system (CNS)
complication of mumps virus infection is aseptic meningitis (in up to 15% of cases) [159, 160,
161]. Mumps epidemics are usually caused by airborne transmission of mumps virus (MuV)
and have high morbidity in non-immunized children. Massive vaccination programs have
decreased the incidence of MuV infection worldwide. The annual incidence of mumps in the
absence of immunization was in the range of 100–1000 cases/100 000 people, outbreaks have
not been completely eliminated even in populations with high vaccination coverage [162].
Laboratory confirmation of mumps infection can be made by the detection of immunoglobulin
M (IgM) antibodies specific to mumps virus in acute-phase serum samples (gold standard for
mumps diagnosis). Mumps virus can be detected from fluid collected from the parotid duct,
other affected salivary gland ducts, the throat, from urine, and from cerebrospinal fluid (CSF).
Parotid duct swabs yield the best viral sample. With previous contact with mumps virus either
through vaccination or natural infection, serum mumps IgM test results may be negative; IgG
test results may be positive at the initial blood draw. The serologic tests available for laboratory
confirmation of mumps acute infection and confirmation of previous exposure to mumps vary
among laboratories. Tests for IgM antibody includes Enzyme Immunoassay (EIA): a highly
specific test for diagnosing acute mumps infection and Immunofluorescence assay (IFA) a test
that is relatively inexpensive and simple, but the test is particularly susceptible to interference
by high levels of mumps-specific IgG. A significant rise in IgG antibody titer, in acute-and
convalescent-phase serum specimens is a positive result of infection. The presence of mumps-
Figure 5. HCV Testing Algorithm and molecular assays.
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specific IgG, detected using a serologic assay (EIA or IFA), is considered evidence of mumps
immunity but does not predict the presence of neutralizing antibodies or protection from
mumps disease [163]. A near patient test (NPT) for the detection of mumps-specific IgM in
oral fluid specimens was developed and evaluated using 196 oral fluid specimens from
suspected cases of mumps and measles. Compared to EIA, the sensitivity, specificity, positive
and negative predictive value of the mumps IgM NPT were 79.5%, 100%, 100%, and 72.6%,
respectively. Mumps IgM NPT is rapid and simple to perform for confirmation of a clinical
diagnosis. The NPT strip is also a suitable matrix for preserving nucleic acid, enabling virus-
specific RT-PCR to be performed [164]. Standard diagnostics that detect virus or virus-specific
antibody are dependable for confirming primary mumps infection in immunologically naïve
persons, but these methods perform inconsistently for individuals with prior immune
exposure. Detection of activated mumps-specific antibody-secreting B cells (ASCs) by an
enzyme-linked immunospot (ELISPOT) assay has the potential for use as an alternative
method of diagnosis when suspect cases cannot be confirmed by detection of IgM or virus.
The mumps-specific memory B cells are detected at a much lower frequency than measles-or
rubella-specific cells, suggesting that mumps infection may not generate robust B-cell memory
[165]. Successful virus isolation by cell culture should always be confirmed by immunofluor‐
escence with a mumps-specific monoclonal antibody or by molecular techniques such as RT-
PCR, nested-PCR or real-time RT-PCR [166-168]. In patients vaccinated, pre-existing vaccine-
induced antibodies. Moreover, acute infection has to be demonstrated by direct detection of
the virus by viral isolation or genomic amplification. RT-PCR allows a diagnosis and also forms
the basis for genotype characterization by sequencing the SH gene, useful tool for mumps
surveillance, management and control, according to WHO recommendations. Virus genotyp‐
ing allows the building of a sequence database that will help to know transmission pathways
of mumps strains circulating in the world and to distinguish wild-type mumps virus from
vaccine virus [169]. Standard RT-PCR to detect the SH gene of mumps virus can be used to
detect mumps RNA in clinical samples or in infected cell culture [170]. The sequence of the
PCR product containing the coding region of the SH gene can be used to determine the viral
genotype [171]. A multiplex real-time RT-PCR test for the detection of RNA from mumps virus
in patient specimens, using primers and probes that target the mumps SH gene [172]. Several
test of real-time RT-PCR are performed with TaqMan Assay [173]. A multiplex real-time RT-
PCR assay, for rapid mumps diagnosis in a clinical setting. The assay used oligonucleotide
primers and a TaqMan probe targeting the mumps SH gene. This test showed 100% correlation
with results from viral culture. [172]. Other qRT-PCR assay is directed to the mumps virus F
gene [174]. Recently, by RT-PCR it was detect a case of corneal endothelitis following the
mumps parotitis [175].
7. Measles virus
Measles produces a highly contagious respiratory infection and may cause extensive epidem‐
ics. Measles is one of the most important causes of child morbidity and mortality. [176]. A safe
and efficacious live attenuated virus vaccine is available toward global measles control [177,
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178]. Measles vaccination is highly effective, safe and relatively cost-effective and has inter‐
rupted measles transmission in most parts of the world [179]. Despite tremendous achieve‐
ments towards global measles mortality reduction and measles elimination goals, globally, in
2010, there were 327305 measles cases reported and an estimated 139300 measles deaths) [180,
181]. Mortality is highest in children and most acute measles deaths are due to secondary
infections that result from a poorly understood measles-induced suppression of immune
responses [182]. In addition to the risks of acute infection, children under the age of 2 years
are also vulnerable to development of subacute sclerosing panencephalitis (SSPE), a progres‐
sive, uniformly fatal neurologic disease associated with persistent measles virus infection of
the nervous system, have documented high levels of antibody to measles virus [183]. Other
diseases related to measles are systemic lupus erythematosus [184] and multiple sclerosis [185].
The measles virus is a member of the Morbillivirus genus of the family Paramyxoviridae. The
virions are pleomorphic and range in size from 100 to 300 nm. The measles virus is antigenically
stable and genetic differences are few among vaccine strains. Wild-type viruses are more
variable. Several different genotypes of wild measles virus are currently circulating worldwide
and this genetic variation provides the basis for the application of molecular epidemiological
techniques to study the transmission of measles virus [186]. Laboratory confirmation of
clinically diagnosed measles was traditionally based on methods such as immunofluorescence
antibody for detection of viral antigen and haemagglutination inhibition (HI), haemolysin
inhibition, complement fixation, and plaque-reduction neutralization (PRN) for detection of
measles antibody in serum (Table 4) [187]. Currently, detection of measles-specific IgM
antibody and measles RNA by real-time RT-PCR are the most common methods for confir‐
mation of measles infection [168]. Initially laboratory confirmation of cases of measles infection
is performed by detection of measles-specific immunoglobulin M (IgM) antibodies, the test of
choice for rapid diagnosis of measles cases in a single serum specimen collected within the
first few days of rash onset, usually become detectable in serum after four days post onset of
rash (90-100% sensitivity) and decline rapidly after one month. The virus can be detected in
serum samples, blood spots, throat swab (or nasopharyngeal swab), urine and or collection of
both respiratory and urine samples that can increase the likelihood of detecting virus. [188].
Oral fluids can also be used to detect viral ribonucleic acid (RNA) [189]. The enzyme immu‐
noassay is the most commonly used method for detecting measles-specific IgM or IgG
antibodies. Both capture and indirect formats for IgM detection are available commercially.
Some tests available are LIAISON IgM measles (DiaSorin, Saluggia, Italy) a new automated
chemiluminescence immunoassay and the enzyme immunoassay (EIA) Enzygnost (Siemens,
Marburg, Germany), which have a a sensitivity of 93.7% and 98.8%, whereas the specificity
was 96.8% and 97.9%, respectively [190]. DiaSorin Liaison (Saluggia, Italy) is other option for
measles diagnosis, with a sensitivity and specificity for measles IgM of 92% and 100%
respectively [191]. Commercially, there are some test directs to simultaneous detection of
measles and rubella as Enzygnost (Siemens) and Platelia (Bio-Rad), useful for detecting IgM
against measles and rubella [192].
In acute, uncomplicated measles, there is a significant rise in measles-specific IgG antibodies
between acute-and convalescent-phase serum specimens. A positive test result for specific IgG
antibodies in a serum indicates past infection with measles virus or measles vaccination, but
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does not ensure protection from infection or re-infection. Screening the young adult population
about to enter college or the military, pregnant women, and other individuals at risk, for
seropositivity, is a valuable tool for determining their immune status.
LABORATORY TEST
Serological assays
Using serum sample
Detection of IgM antibody by indirect IgM ELISA, IgM-capture
ELISA or EIA for IgM
Detection of IgG antibody by IgG ELISA
Virus neutralization test
HI
Cell culture and immunofluorescence microscopy
Using urine, nasopharyngeal swabs or blood
lymphocytes and detect to virus using specific
measles antibody
NAT analysis
measles RNA can be detected from nasopharyngeal swab, urine or
peripheral blood lymphocytes (oral fluid/ throat swabs) up to 5 days
post disease manifestation.
RT-PCR, RT-nested PCR, Real-Time RT-PCR and sequencing
Table 4. Laboratory diagnosis for measles in clinical materials.
Enzyme-linked immunosorbent assay (ELISA) is normally used to quantify the amount of
serum IgG antibodies against measles (measles in addition to mumps, rubella, and varicella-
zoster virus, MMRV). However, a multiplex immunoassay for the simultaneous detection of
antibodies against MMRV showed be a good alternative to conventional ELISAs and suitable
for use in serosurveillance and vaccine studies [193]. An enzyme linked Immunosorbent
commercial assay is Captia Measles IgG based (Trinity, Biotech, USA). In countries where
disease prevalence is low, intensified surveillance typically implemented during and after an
importation will result in some false positive IgM results since no assay is 100% specific. So, it
is necessary to introduce other techniques of diagnosis related to ARN genome. In the Fifth
Hands-on Training on the Laboratory Diagnosis of Measles and Rubella focusing on Molecular
Detection and Sequence Analysis, in Hong Kong, China. It was exposed the need of introduce
the molecular detection of measles and rubella viruses using new real-time polymerase chain
reaction (PCR) as well as conventional PCR, quantitative real-time PCR and others molecular
techniques such as sequencing. Dr Paul Rota (Chief, Measles Virus Section, Centers for Disease
Control and Prevention USA), presented on the use of real-time and conventional RT-PCR for
case classification and molecular surveillance of measles virus. These tests can detect 10-100
copies of RNA/sample in a high throughput format and produce results within two hours. It
can help to confirm a case when serologic results are inconclusive but negative results do not
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rule out a case. These molecular tests are more sensitive than conventional (endpoint) RT-PCR.
Sequence information from the conventional PCR is required for genotype assignment and
confirmation of vaccine reactions [194].
Measles RNA can be detected (oral fluid/ throat swabs) up to 5 days post disease manifesta‐
tion. Molecular assays to measles virus includes measles H (haemagglutinin) gene real-time
PCR and hybridization [195] and nucleic acid sequence analysis of the nested N-gene PCR
amplicons (nucleocapsid) [196, 197]. A nested reverse transcriptase PCR (RT-PCR) that detected
measles virus (MV) from dried filter papers was set up using MV infected cells diluted in sterile
phosphate-buffered saline. Although, the nested RT-PCR results of low titer viruses dried onto
filter papers are not reproducible and reliable [198, 199]. Detection of RNA in PBMC by RT-
PCR is the most effective method for diagnosis of measles. A study performed in 2010, analyzed
sixty-three throat swabs, 84 peripheral blood mononuclear cell (PBMC) samples, and 85 plasma
samples were collected from 85 cases of suspected measles. The percentage of positive results
from PBMC by RT-PCR and virus isolation was 100 and 91.7%, respectively. The percentage of
positive results from throat swabs by RT-PCR and virus isolation was 91.2 and 52.8%, respec‐
tively [200]. Measles can produce congenital infections with a risk of neurological complica‐
tions in the newborn. Mother-to-child transmission of the measles virus, it has been widely
documented in the newborns either by RT-PCR in saliva or by IgM detection in blood. An early
viral  RT-PCR  detection  allows  successful  immunoglobulin  prophylaxis  in  one  newborn
avoiding the development classical or neurological clinical signs of measles infection [201].
Molecular detection of measles virus has been optimized by amplification of nucleocapsid (N)
and human RNase P mRNA for a one-step quantitative reverse transcription (qRT)-PCR [202].
The qRT-PCR for measles diagnosis can use SYBR Green or TaqMan (ABI) in real-time reverse
transcription-polymerase chain reaction (RT-PCR) assays. For the real-time RT-PCR, primer
sets are design from a region of the MV H gene of the Edmonston strain (genotype A) and a
TaqMan probe specific for the H gene of genotype D MV [203]. Currently, is possible estimate
the titer of measles, mumps and rubella (MMR) viruses by a TaqMan-based real-time reverse
transcription-polymerase chain reaction (qPCR-RT) assay optimized in infected cell culture
supernatants [204]. For genetic typing of measles virus in clinical samples is xMAP technolo‐
gy that employs specific oligonucleotide probes of genotypes D4, D6 and D7 of virus [205].
Other alternative employed for the genotype analysis of measles virus is sequencing of the 450
nucleotide of nucleoprotein gene (N450) that contributes to the genetic characterization of wild-
type measles viruses and offers data in the study of viral transmission pathways. N450 is
amplifying with the primer pair, MeV216/MeV214. It is clear that the molecular tools improve‐
ment the molecular characterization of circulating measles viruses globally and provides
enhanced quality control measures [206]. Demonstration of the usefulness of molecular tests in
the diagnosis of measles during outbreaks or epidemic peaks was reported in an outbreak in
Paris (France) in 2011. 171 oral fluid samples and 235 serum samples collected from 270 patients
were tested using a novel one-step real-time RT-PCR assay. This study showed that the detection
rate of MV-RNA by RT-PCR was 98% (100/102) for oral fluid and 95% (97/102) for serum samples.
The detection rate of MV-IgM was 85% (87/102). In addition, it was found than during the early
stage of infection, the MV-RNA viral load in serum was lower in patient’s positive than in those
negative for MV-IgG [207]. The detection and identification of the virus in cell culture may take
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several weeks. The samples should undergo virus isolation on sensitive cell lines, such as B95a
cells. Measles virus can be isolated from clinical specimens, including; throat swab, conjuncti‐
val swabs, nasopharyngeal aspirates or urine [208].
8. HIV
Acquired Immunodeficiency Syndrome (AIDS) is one of the most critically acclaimed endemic
diseases, caused by two lentiviruses HIV-1 and 2. Human immunodeficiency virus (HIV) is
the pathogen causing the acquired immunodeficiency syndrome (AIDS) [209, 210]. HIV is an
enveloped virus with tropism for CD4+lymphocytes and monocytes. HIV is classified in the
family Retroviridae, subfamily Lentivirinae, and genus Lentivirus. HIV comprising a single
stranded, positive-sense ribonucleic acid (RNA) genome of about 9.7 kilobases. From the 5'
end of genome are located the three genes that characterize retroviruses: gag-pol-env. The gag
gene codes for the internal structural proteins, the pol gene for the three viral enzymes, and
the env gene for the envelope glycoproteins. LTR (Long Terminal Repeat) sequences are found
at each extremity of the genome, containing the signals for the regulation of expression of the
viral genes. The genome also has six additional genes called "accessory" genes: vif, nef, vpr, tat,
rev and vpu (HIV-1) or vpx (HIV-2) [211]. There are two strands of HIV RNA and each strand
has a copy with nine genes, which encode 15 proteins. The RNA is surrounding by a cone -
shaped capsid which consists of approximately 2000 copies of the p24 viral protein. Surround‐
ing the capsid is the viral envelope. Each envelope subunit consists of two non-covalently
linked membrane proteins: glycoprotein (gp) 120, the outer envelope protein, and gp41, the
transmembrane protein that anchors the glycoprotein complex to the surface of the virion. The
envelope protein is the most variable component of HIV, although gp120 itself is structurally
divided into highly variable (V) and more constant (C) regions. The variability of the HIV
envelope also confers a uniquely complex antigenic diversity. The virion contains three
enzymes necessary for multiplication: reverse transcriptase (enables the viral RNA to be
transcribed into DNA), and endonuclease (enables the DNA to be integrated into the host cell,
the viral genome then becomes proviral DNA) and the protease (enables the virus to mature
at a late stage in the cycle of intracellular multiplication). The presence of two copies of the
retroviral genome in each particle promotes genetic recombination between the RNAs. This
and the high error rate of the viral reverse transcriptase leads to considerable genetic variation
in the viral progeny. AIDS is characterized by the selective targeting of the CD4+/CD8+T cells
by HIV which fatally impairs the immune system. The window period for this retrovirus is
from several weeks to few months altogether before detection of earliest antibodies in blood
serum raised against HIV [210]. HIV infection is one of the major threats to human health due
to the lack of relevant vaccine and drugs to cure AIDS. Its early diagnosis is thus important in
controlling HIV transmission. With acute HIV infection, high levels of infectious virus are
detectable in serum and genital secretions. The rate of transmission during acute HIV infection
is higher than the established HIV infection, for this reason, new HIV testing strategies need
to focus on sensitivity, especially for this highly contagious phase immediately after infection.
There are two types of virus, HIV-1 and HIV-2, which are further divided into groups and/or
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subtypes. The pandemic is caused by HIV-1 group M. HIV-1 and HIV-2 have differences as
clinical progression of the disease is slower and mother-to-child transmission is less likely with
HIV-2 than with HIV-1 (maternal-fetal transmission < 2% in the absence of treatment).
Recombinant HIV strains are known as CRF (Circulating Recombinant Forms). Although
HIV-2 is also associated with AIDS, it is not transmitted as readily and, generally speaking,
progression toward immunodeficiency is much slower in individuals with an HIV-2 infection.
HIV-1 is responsible for a chronic infection that gradually develops and causes the destruction
of the body's CD4+T lymphocytes. HIV-1 is responsible for a chronic infection that gradually
causes the destruction of CD4+T lymphocytes [212]. To detect a HIV infection several tests are
used to analyze the HIV infection status of a patient, evaluate the progression of disease, and
monitor the effectiveness of antiretroviral therapy (ART). HIV infection can be diagnosed by
direct visualization of virions or electron microscopy; cultivation by lymphocyte culture;
measurement of HIV-specific serologic responses; detection of viral antigens; and detection of
viral nucleic acids [213]. For many years, laboratory diagnosis of HIV is based on the identi‐
fication of HIV antibodies using immuno-enzymatic (ELISA) tests or other immunological
techniques of equivalent sensitivity. Still considering the limitation of this approach in the
known ‘window period’ between the time of infection and the initial instance of detectable
antibody, this may last for several weeks. Primary infection is asymptomatic in more than 50%
of cases. In the remaining cases, symptoms appear two to three weeks after infection and
clinical signs usually resemble those of flu-like or mononucleosis syndromes. Plasma viraemia
levels are generally high (≥106 copies of viral genome/ml) during primary infection.
An assay useful in Multispot HIV-1/HIV-2 Rapid Test (BIO-RAD) directed to a rapid test for
detection and differentiation of HIV-1 and HIV-2 antibodies in human serum and plasma. This
test have a time of results of 10 minute and shows HIV-1 sensitivity: 100%, HIV-2 sensitivity:
100% and specificity: 99.9% [214]. BIO-RAD also has an assay know as HIV-1/HIV-2 PLUS O,
an ELISA-immuno assay utilizing recombinant proteins and synthetic peptides for the
detection of antibodies to HIV-1 (groups M and O) and/or HIV-2.
New HIV screening tests approved by the US FDA in 2010-2011 include immunoassays capable
of detecting p24 antigen and HIV antibody simultaneously. The fourth generation combo
assays could reduction the window period due to their ability to detect viral protein s in
addition to IgG and IgM class antibodies against both HIV-1 and HIV-2 [215], but the moni‐
toring of HIV disease progression is mostly accomplished by the quantitation of CD4 T cells
and viral RNA [216]. The use of combined ELISA tests called “4th generation” tests, enables
for more effective early detection of infections which are very often asymptomatic. Also, these
assays can detect acute and chronic infections. An example is the ARCHITECT HIV Ag/Ab
Combo assay (Abbott Diagnostics), which uses anti-HIV-1 p24 antibodies as reagents to detect
HIV-1 p24 antigen, thereby decreasing the window period and improving early detection of
HIV infection. The assay is useful to determine the presence of HIV-1 p24 antigen, antibodies
to HIV-1 (group M and group O), and antibodies to HIV-2 in human serum or plasma using
chemiluminescent microparticle immunoassay A technology. The test has an analytical
sensitivity of <50 pg/mL for HIV-1 p24 antigen [217]. There are others fourth-generation human
immunodeficiency virus-1 (HIV-1) screening assays as the AxSYM HIV Ag/Ab Combo (Abbott
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diagnostics, Delkenheim, Germany), Elecsys 2010 HIV Combi (Roche Diagnostics GmbH,
Mannheim, Germany) and Vidas HIV Duo Quick (Biomerieux, France). All of the assays had
sensitivities of 100% on clinical samples. The specificities of the AxSYM, ARCHITECT, Elecsys
2010 HIV Combi, and Elecsys HIV Combi PT were 99.6, 99.6, 99.0, and 99.5%, respectively
[218]. Genscreen Ultra HIV Ag-Ab is other new version of the HIV p24 antigen and antibody
combination assays [218]. The commercial ELISAs such as Vironostika HIV Ag/Ab, Enzygnost
Anti-HIV 1/2 Plus Genscreen HIV-1/2 Version 2 and INNO-LIA HIV I/II are suitable tools for
making HIV test performance accessible to people [219]. The accurate diagnosis of HIV
infection demands that to consider a positive result, at least three assays with different
antigenic base should be used, one of them, Western-Blot being mandatory for confirmation.
Confirmatory techniques which are used most frequently they are the Western Blot (WB) and
the recombinant immunoblot or immunoassay online (LIA) who have at least the same
sensitivity than ELISA and a higher specificity. Both techniques they can incorporate antigens
of HIV-2. It detects antibodies against the glycoprotein gp160 envelope, gp120 and gp41, p55,
p24 and p17 encoded-gag and p66, p51 and p311. The interpretation of the results is crucial; a
negative test is the total absence of reactivity. To assess, the positivity numerous criteria
applied, according to the Center for Disease Control (CDC) a positive result occurs with at
least 2 bands of p24, gp41, and gp160gp120 are detected. WHO recognizes a positive test with
2 bands. The ARC (American Red Cross) indicates three bands, one of each structural gene,
and the Consortium for Retrovirus Serology Standardization indicates at least one of gp120 or
gp160 and one of p24 or p31 [220, 221]. It is interpreted as an undetermined result, any reactivity
that does not meet the minimum criteria of positivity. Since, the causes of WB indeterminate
are diverse and they may correspond to early phases or advanced stages of infection associated
to severe immune impairment, or to the presence of immune complexes than can reduce the
antibodies circulating, between other causes. Detection of some band of envelope with or
without bands of gag gene, may be due to HIV infection. In these cases, is necessary performed
others confirmatory tests as LIA and sometimes complement them with the determination of
proviral DNA or viral load or p24 antigen to assess a possible primoinfeccion. In any case on
an indeterminate WB is required a new sample [222-224]. The comparison between the Ag/Ab
combo assay and RNA viral load showed that in an acute HIV infection in human gave a similar
result. HIV Combo detected 97% of infections acute. The ARCHITECT HIV Combo assay can
detect p24 Ag when RNA is above approximately 58,000 copies/mL [225]. However, the
comparison between the results of HIV RNA nucleic acid test (NAT) and 4th-generation
Ag/Ab assay (ARCHITEC HIV Ag/Ab Combo [HIV Combo] assay, Abbott Diagnostics) in 2744
HIV antibody-negative samples were identified fourteen people with acute HIV infection (HIV
antibody negative/NAT positive). The HIV Combo assay detected nine of these individuals
[226 delete these rows, from the stage word to the HIV Word [226In the 2012 HIV Diagnostics
Conference: the molecular diagnostics perspective, gives in Atlanta, GA, USA, 12–14 December
2012. The forum was foccusing in the evaluation of molecular diagnostics and their role in HIV
diagnosis. Many scientific presentations exposed the role played by RNA testing and new
developments in molecular diagnostics, including detection of total and integrated HIV-1
DNA, detection and quantification of HIV-2 RNA, and rapid formats for detection of HIV-1
RNA [227]. HIV infection monitoring is based on counting the number of CD4+lymphocytes
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and quantification of plasma viral RNA. These tests are performed every 6 months if the CD4
count is > 500/mm3 and every 3 to 4 months if the CD4 count is between 200 and 500/mm3.
Plasma viral load is measured using quantitative tests based on molecular tools: gene ampli‐
fication (PCR-polymerase chain reaction, LCR-ligase chain reaction, TMA-transcription
mediated amplification, NASBA-nucleic acid sequence based amplification) or hybridization
followed by signal amplification (bDNA-branched DNA). Most tests have sensitivity of the
order of 50-100 copies/ml. Although the new HIV diagnostic algorithm relies on RNA assays
as a supplemental test, it is not clear how accessible these assays will be for clinical laboratories.
Currently, only one HIV RNA test is approved by the US FDA for HIV diagnosis (Hologic
Gen-Probe APTIMA HIV-1 RNA Qualitative Assay) and some clinical laboratories may need
to send specimens out for RNA testing. Currently, molecular diagnosis of HIV infection is only
used as a complementary diagnosis although viral load test is used to monitor disease
progression and responsiveness to antiviral therapy. Recently, it was proposed to the first-line
HIV molecular techniques performed on a routine basis routed to the use of HIV molecular
tools for the screening of blood products, organs and tissue from human origin. Directed to
medically assisted procreation and in neonates from HIV-infected mothers [228]. In 2012 HIV
Diagnostics Conference was presented the design of a new HIV-1 proviral DNA assay capable
of detecting two copies of HIV-1 DNA in a qualitative format and quantitatively of three to
30,000 copies per ml. Since the lack a nucleic acid test for HIV-2, in this meeting was described
a novel HIV-2 RNA viral load assay based on the 5´ long terminal repeat of HIV-2, with a lower
quantification limit of 29 infectious units per ml. In addition, an assay capable of detecting
HIV-2 proviral DNA, which combines three separate amplification reactions from three
regions of the proviral genome, detected both A and B HIV-2 subtypes at between five and ten
copies of the HIV-2 proviral genome [228]. For other side, HIV-1 detection in plasma samples
with a molecular beacon-based multiplex NASBA assay of a region in the HIV-1 pol gene
showed a limit of quantification of the assay was <1000 copies/ml for HIV-1 with 98% sensi‐
tivity and 100% specificity [229]. Also, it was reported the detection and quantification of HIV-1
group O RNA in plasma by an RT-qPCR assay [230]. In addition, there are several HIV
molecular assays showed in the table 5 [231].
Routine follow-up of HIV-infected individuals includes measurement of CD4+T cell count to
evaluate the immune status, of viral load to assess virus replication directed to events of
therapeutic failure (therapeutic escape), and of changes in the viral genome to characterize
resistance to drugs and tropism. Genotype resistance testing can detect a potential viral escape
due to poor compliance with the treatment regimen, metabolic problems or the selection of
resistant mutants. In summary, the diagnosis of HIV infection is established by one of the
following methods: detecting antibodies to the virus; detecting the viral p24 antigen; detecting
viral nucleic acid; or culturing HIV.
The most widely used test is the detection of antibodies to HIV [232]. Rapid serological tests
take only 15 minutes with acceptable specificity and sensibility. But, there is the possibility of
have a negative false result with them. NATs are assays more sensitive in HIV diagnosis, but
more expensive. The expanded use of point-of-care (POC) tests to HIV testing plays an
important role in HIV prevention, both in developed and in developing countries [233]. The
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access to immediate HIV test results could improve the application of prophylactic regimens
to reduce vertical transmission when used intrapartum or postpartum [234].
The analysis of the cost-effectiveness of initial diagnosis with a rapid HIV test, to screen out
HIV-uninfected infants shows that in the comparison of DNA-PCR and rapid HIV test
approaches, the first assay identified 94.3% (91.8–94.7%) of HIV-infected infants, as compared
with 87.8% (79.4–90.5%) for the latter. Moreover, the total cost of the POC testing program was
about 40% less than that of DNA-PCR ($59 vs. $38 per infant aged 6–9 months). Assessing the
cost-effectiveness of several HIV testing as well as establishing a specific threshold of positivity
for routine testing of HIV dignosis will be critical in AIDS control [235, 236]. Despite the global
effort to control the AIDS pandemic, human immunodeficiency virus (HIV) infection continues
to spread relatively unabated in many parts of the world. As the AIDS epidemic continues is
necessary establish new strategies of prevention, treatment and molecular diagnostics assays
to discriminate "window phase" infections from those that are serologically positive. There is
opportunity to implement and evaluate the incremental diagnostic usefulness of new test
modalities that are based on sophisticated molecular diagnostic technologies and that can be
performed in settings where laboratory infrastructure is minimal [237]. Human immunodefi‐
ciency virus type 1 (HIV-1) is a highly diverse virus, a global scale, and within individual HIV-1
infected subjects [238]. The genetic variants constituting the viral population are called
haplotypes, and these haplotypes form a viral quasispecies [239]. This viral diversity is highly
METHOD AND NAME TEST
DNA/RNA qualitative assays used to diagnosis HIV
APTIMA HIV-1 RNA Qualitative assay or Procleix HIV-1/HCV Assay (Gen Probe)
RNAviral load testing used for clinical diagnosis and/or monitoring of HIV-1
COBAS AmpliPrep/TaqMan HIV-1 (Roche Molecular)
Versant HIV-1RNA (Siemens)
NucliSens HIV RNA QT (bioMérieux)
RealTime m2000 HIV-1 (Abbott Molecular)
Genotyping drug used to Antiretroviral drug resistance
TruGene HIV-1 genotyping (Siemens)
ViroSeq HIV-1 genotyping (Abbott Molecular)
HIV PRT GeneChip assay (Affymetrix)
HIV RT Line Probe assay (Innogenetics)
Phenotyping drug used to Antiretroviral drug resistance
AntiVirogram assay (Virco Lab)
Trofile (MonoGram BioSciences)
SensiTrop II HIV (Pathway Diagnostics)
Information based on Tang YW, et al. 2012 [231].
Table 5. Main molecular diagnostics methods for HIV-1.
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relevant on pathogenesis, drug resistance, and vaccine development. Currently, virus popu‐
lations can be studied much faster using next-generation sequencing (NGS) platforms. NGS
is a valuable tool for the detection and quantification of HIV-1 variants in vivo [240, 241]. As
Venet exhibited in 2004, a major evolution in the near future will be the generalization of NAT
for the diagnosis of viral etiology in patients, mostly with respiratory, CNS or hepatic diseases.
Major technical improvements have been made to avoid obstacles that still limit this general‐
ization, related to genetic variability of viruses, multiplex detection or contamination risk [242].
Real-time amplification has allowed the development of new NAT platforms and the intro‐
duction of others techniques as NGS than contributes with data that support to global
diagnostic [243].
In this chapter was presented the some methods applied to diagnosis and monitoring of an
infectious disease of viral etiology with global incidence, such as hepatitis, mumps or influenza
that have been authorized by WHO and CDC. In addition, new applications of molecular
techniques that facilitate fast identification of the etiology of an infectious disease were
presented.
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